Case ReportPublished 9 October 2026Durable biochemical and radiographic response during toripalimab treatment in MSI-high/TMB-high mCRPC: a case reportJunhang Ding · Zhengxin Liu · Jinyu Tian · Feng Wang · Chuan LiuFrontiers in Oncologydoi 10.3389/fonc.2026.1907524
Systematic ReviewPublished 5 June 2026Efficacy and safety of PD-1 inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysisAbdullah Alabbasi · Muhanad Alzahrani · Ziyad Alzahrani · Faris Sultan · Maha AlQahtani · Alaa SultanOncology Reviewsdoi 10.3389/or.2026.1745071
Case ReportPublished 23 January 2026Case Report: Durable response to PD-1 blockade after failure of ALK-targeted therapy and chemoimmunotherapy in ALK-positive large B-cell lymphomaGuilherme Gasparini Spiandorelo · Ahmed Alnughmush · Olivia Crum · Dragan Jevremovic · J. C. VillasboasFrontiers in Hematologydoi 10.3389/frhem.2025.1683981
